8:00 am Check-In & Networking

8:50 am Chair’s Opening Remarks

Showcasing Brand New Approaches to Conjugate Design to Overcome the Limitations of Traditional ADCs & Widen the Therapeutic Index

9:00 am Hormone-Peptide Conjugate: Next Generation Targeted Therapy

Synopsis

  • Explore a paradigm shift in conjugate design, focusing on the mechanism rather than the molecule, to unlock new avenues for targeted therapy innovations
  • Embrace innovation, this conjugate design bypasses traditional linker-based approaches, with the hormone directly fused to the lytic peptide, optimizing delivery and enhancing therapeutic efficacy
  • Discover how the unique design of hormone-linked lytic peptides, leveraging electrostatic interactions for targeted cytotoxicity, offers a safer and more effective approach to cancer therapy

9:30 am Spotlighting Synergy: Embracing a Holistic & High-Throughput Approach to Revolutionise the Development of Fragment-Based Novel Conjugate Drugs

  • Arne Scheu Chief Executive Officer, Valink Therapeutics

Synopsis

  • Explore the paradigm shift towards a holistic approach to conjugate design, where equal emphasis is placed on optimizing each component – from payload to linker to targeting binders – to maximize therapeutic efficacy and minimize off-target effects
  • Delve into the innovative methodologies enabling rapid iteration and high-throughput screening of conjugates, allowing for the creation of thousands of optimized candidates in mere weeks, revolutionising the pace and scale of conjugate development
  • Discuss the transformative potential of integrated whole molecule approaches in driving forward the field of conjugate therapies, ushering in a new era of precision medicine by leveraging comprehensive optimization across all facets of conjugate design and development

10:00 am Speed Networking

Synopsis

Join us for an exhilarating session of speed networking to kick-start the conference. Connect with industry peers, exchange insights, and forge valuable partnerships in just minutes, accelerating your professional network in the dynamic and fast-growing world of novel drug conjugates.

11:00 am Antibody-Like Domains: Pioneering Novel Conjugates for Inflammation Therapy

Synopsis

  • Explore the unique properties of soloMERs and their potential as versatile targeting moieties for novel conjugate designs in inflammation therapy
  • Discuss the evolution of soloMERs from traditional ADCs in oncology to novel applications in inflammation therapy, highlighting the adaptability and versatility of the platform in addressing diverse disease indications
  • Delve into the frontier of novel anti-inflammatory payloads, showcasing the potential for targeted delivery of novel therapeutics in inflammation-related disorders

11:30 am A Transformational Drug Delivery Technology: Using Stabilised PepPeptides to Deliver Proteins and RNA-Targeting Payloads to the Cell Interior

Synopsis

  • Improving cellular penetration and stability of biomolecular medicines.
  • Enabling the delivery of diverse payloads in specific tissues in the body, allowing for a disease-agnostic approach.
  • Varying the number and placement of staples on peptides to determine the most effective conformation in combination with different payloads 

12:00 pm Lunch & Networking

Highlighting Application of Oligonucleotide Conjugates for Precise Modulation of Gene Expression in Diverse Therapeutic Areas

1:00 pm Overcoming Endosomal Entrapment in Oligonucleotide Delivery

  • Miriam Bujny Chief Development Officer (CDO), Sapreme Technologies

Synopsis

  • Explore the challenges of endosomal entrapment in delivering oligonucleotide payloads and the critical role of endosomal escape enhancers in maximising intracellular delivery and therapeutic efficacy
  • Discuss the evolution of antibody-oligonucleotide conjugates as promising modalities for RNA therapies, and the imperative of enhancing endosomal escape for effective delivery beyond hepatic targets
  • Showcasing a diverse portfolio of proof-of-concept studies demonstrating the efficacy of endosomal escape enhancers in facilitating intracellular release of oligonucleotide payloads, paving the way for transformative therapeutics with the potential to revolutionize patient care

1:30 pm GEENIE: A Novel Protein Nanoneedle for Targeted Intracellular Delivery

Synopsis

  • Mechanism of cell entry: Bypasses endosomes to deliver a diverse range of therapeutic cargoes directly into cells Therapeutic Applications: Enhances the efficacy of drugs, nucleotides, and other therapeutic agents by avoiding degradation
  • Innovative Design: Designing protein nanoneedles for targeted delivery without using antibodies

2:00 pm Gene Silencing Redefined: Unlocking the Potential of Self-Delivering siRNAs

  • Merle Fuchs Chief Executive Officer, PRAMOMOLECULAR GmbH

Synopsis

  • Which delivery technologies are gaining acceptance?
  • Advantages of lipid siRNAs
  • PRAMOMOLECULAR´s self-delivering siRNAs

2:30 pm Afternoon Break & Networking

  • Merle Fuchs Chief Executive Officer, PRAMOMOLECULAR GmbH

Harnessing Bispecific Drug Conjugates For Enhanced Target Specificity & a Reduction in Off-Target Toxicity

3:00 pm New PEGylated Bispecific ADC

  • Shu-Min Liu Chief Executive Officer, Shenzhen Enduring Biotech, Ltd.

Synopsis

  • Achieving excellent tumour penetration
  • Optimising internalization and lysosome trafficking, no efflux
  • Benefiting from no Fc induced toxicity
  • Highly selective toward tumor cells

3:30 pm Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBIâ„¢ Platform

Synopsis

  • Advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumour proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations
  • Challenges and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting
  • Benefits of GlycOBIâ„¢ Platform: Producing homogenous ADCs without genetic modification, enhancing stability and anti-tumor activity with hydrophilic linkers, and simplifying the Chemistry, Manufacturing, and Controls (CMC) process

4:00 pm Targeted Delivery of Synthetic Cargos via Bispecific Antibodies: An Affinity-Based Conjugation Platform

Synopsis

  • Utilising bispecific antibodies to precisely bind and deliver synthetic cargos to specific cellular targets
  • Enhancing the specificity and efficiency of synthetic cargo delivery to designated cells
  • Offering a versatile platform for targeted therapeutic applications by leveraging affinity based interactions for precise cargo delivery

4:30 pm Chair’s Closing Remarks

4:30 pm End of Day One